261 related articles for article (PubMed ID: 1687043)
1. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
Martino E; Balzano S; Bartalena L; Loviselli A; Sica V; Petrini L; Grasso L; Piga M; Braverman LE
J Endocrinol Invest; 1991 Nov; 14(10):847-51. PubMed ID: 1687043
[TBL] [Abstract][Full Text] [Related]
2. Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease.
Roti E; Gardini E; Minelli R; Bianconi L; Braverman LE
Metabolism; 1993 Apr; 42(4):403-8. PubMed ID: 8487661
[TBL] [Abstract][Full Text] [Related]
3. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
4. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
[TBL] [Abstract][Full Text] [Related]
5. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
[TBL] [Abstract][Full Text] [Related]
6. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
[TBL] [Abstract][Full Text] [Related]
7. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
8. Long term treatment of Graves' hyperthyroidism with sodium ipodate.
Shen DC; Wu SY; Chopra IJ; Huang HW; Shian LR; Bian TY; Jeng CY; Solomon DH
J Clin Endocrinol Metab; 1985 Oct; 61(4):723-7. PubMed ID: 3928675
[TBL] [Abstract][Full Text] [Related]
9. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease.
Roti E; Robuschi G; Gardini E; Montermini M; Salvi M; Manfredi A; Gnudi A; Braverman LE
Clin Endocrinol (Oxf); 1988 Mar; 28(3):305-14. PubMed ID: 3168311
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
11. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
[TBL] [Abstract][Full Text] [Related]
12. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
[TBL] [Abstract][Full Text] [Related]
14. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
16. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate.
Karpman BA; Rapoport B; Filetti S; Fisher DA
J Clin Endocrinol Metab; 1987 Jan; 64(1):119-23. PubMed ID: 3782427
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
18. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
[TBL] [Abstract][Full Text] [Related]
19. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
[TBL] [Abstract][Full Text] [Related]
20. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]